



The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments

Mariko Kawamura¹, Yutaro Koide², Taro Murai³, Shunichi Ishihara⁴, Yuuki Takase^{1,5}, Takayuki Muraio⁶,
Dai Okazaki⁷, Takahiro Yamaguchi⁸, Kaoru Uchiyama⁹, Yoshiyuki Itoh¹, Takeshi Kodaira², Yuta
Shibamoto³, Mika Mizuno¹⁰, Fumitaka Kikkawa¹¹, and Shinji Naganawa¹

Figure A) Differences in survival according to the chemotherapy regimen in each FIGO stage
 FIGO I-IIA



FIGO IIB-IVA



FIGO IVB




Figure B) Differences in survival with use of IP vs EP




Figure C) Differences in survival according to the chemotherapy regimen for patients treated with CCRT




Figure D) Differences in survival according to treatment strategy for non-stage IV (only patients treated with the small cell carcinoma regimen)




Table E) Characteristics of patients who died from dissemination to the brain and/or meninges.

| | Age | Tumor size | FIGO 2018 | Treatment strategy | Chemo | Chemotherapy courses |
|---|-----|------------|-----------|----------------------|----------------|----------------------|
| 1 | 51 | 26 mm | IIIC | Surgery+Chemotherapy | CDDP+VP16 | 6 |
| 2 | 41 | 110 mm | IVB | CCRT | wCDDP | unknown |
| 3 | 24 | 20 mm | IIIC | Surgery+CCRT | CDDP+VP16 | 3 |
| 4 | 31 | 18 mm | IB | Surgery+Chemotherapy | CBDCA+VP16 | 4 |
| 5 | 62 | 68 mm | IVB | Chemo | CDDP+VP16 | 5 |
| 6 | 51 | 80 mm | IIIC2 | Chemo | CDDP+CPT11 | 8 |
| 7 | 47 | 66 mm | IVB | Chemo | CDDP+CPT11 | 6 |
| 8 | 34 | 54 mm | IIIC2 | Chemo | CDDP+CPT11 | 8 |
| 9 | 64 | 30 mm | IVB | Chemo | Biweekly CPT11 | 10 |